2018 ANNUAL ASSEMBLY OF MEMBERS
Minutes of the Annual Assembly of Members, held on Tuesday 3 July 2018, 18.00 pm, at Centre de Convencions de Barcelona, Plaça de Willy Brandt 11-14, 08019 Barcelona, Spain
Solid data and the evidence to counsel patients accurately
Cristine Magli, an investigator in the ESHRE-sponsored ESTEEM trial, explains more on the design of the study and why the results provide strong evidence about PGT-A.
A reduced risk of miscarriage
Willem Verpoest, an IVF specialist at the VUB Brussels and co-ordinating investigator of the ESTEEM trial, considers the clinical benefits seen in this ESHRE-sponsored study of aneuploidy screening.
Ageing as 'a process of oxidative stress'
Australian andrologist John Aitken argues that two consequences of male ageing - declining fertility and passing on an ever increasing mutational load to offspring - are each a self-perpetuating function of oxidative stress.
Women who survive cancer less likely to achieve a pregnancy
For the first time, a large population study quantifies the effect of cancer and its treatment on the chances of pregnancy.
No improvement in live birth rates in ESHRE PGT-A trial
Karen Sermon, principal investigator of the ESTEEM trial, reviews the results and implications of this ESHRE-sponsored study of aneuploidy screening.
The new man in the editor's chair
The Dutch gynaecologist Nils Lambalk will take over as editor-in-chief of Human Reproduction in January next year. He talks to Focus on Reproduction about his plans for the journal and the demands which editorship now implies.
No improvement in live birth rate from PGT-A, but markedly fewer miscarriages
Balancing the clinical benefits in miscarriage risk against the non-benefits in cumulative live birth rate.
Think differently
ESTEEM trial co-ordinating investigator Willem Verpoest believes there are important benefits - and messages - to be found in this ESHRE study of aneuploidy screening
New international guidelines
Bart Fauser, one of the principals behind the ESHRE/ASRM Rotterdam diagnostic consensus of 2003, on a new and fuller international guideline on PCOS launched in Barcelona.